Featuring perspectives from Dr Neeraj Agarwal and Dr Emmanuel S Antonarakis, including the following topics:Introduction: ESMO 2026; Recent FDA Approvals (0:00)Selection of Endocrine Therapy — Dr Antonarakis (2:24)Utility of PARP Inhibitors — Dr Agarwal (22:59)AKT Inhibition for PTEN-Deficient Disease — Dr Antonarakis (35:42)Radiopharmaceuticals — Dr Agarwal (45:02)CME information and select publications
Featuring an interview with Prof Karim Fizazi, including the following topics:Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00)Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37)Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47)Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43)Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51)Role of intermittent therapy in the treatment of prostate cancer (38:48)Treatment intensification approaches in prostate cancer (41:38)Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25)CME information and select publications
Featuring an interview with Dr Neeraj Agarwal, including the following topics:Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00)Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13)Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15)Managing treatment-related adverse events from capivasertib (20:08)Case: A man in his late 50s diagnosed with metastatic APMS prostate cancer and a PTEN deficiency who receives capivasertib (29:17)Case: A man in his late 70s diagnosed with high-volume metastatic APMN prostate cancer and a PTEN deficiency who experiences disease progression on androgen deprivation therapy and enzalutamide (40:39)CME information and select publications
Featuring perspectives from Dr Alexandra Drakaki, including the following topics:Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00)Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic progression after 9 cycles of therapy (6:23)Case: A woman in her early 70s with Lynch syndrome and metastatic upper tract bladder cancer receives EV/pembrolizumab and develops myasthenia gravis (13:59)Case: A woman in her late 40s with FGFR3 mutant metastatic bladder cancer receives erdafitinib and experiences rising serum phosphate levels (20:04)CME information and select publications
Featuring perspectives from Dr Alexandra Drakaki, including the following topics:Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00)Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointestinal toxicity — Part 2 (5:37)Case: A man in his early 50s with metastatic bladder cancer receives second-line EV monotherapy intermittently (15:09)Case: A woman in her mid 60s with bladder cancer and a history of rheumatoid arthritis develops oligometastatic progression in the lung and receives EV monotherapy (21:03)Case: A man in his mid 80s with HER2-positive (IHC 3+) metastatic bladder cancer receives trastuzumab deruxtecan and develops ground glass opacities in his lungs concerning for pneumonitis (30:43)CME information and select publications